Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

This was the stock's fourth consecutive day of losses.

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

Attorney Stuart Silverman says the First Circuit’s widening the divide on the False Claims Act’s causation standard adds to the need for the Supreme Court to weigh in.

Celestial discoveries: Paz won the $250,000 top prize for his research on detecting objects in the night sky. Using ...

Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.

"One of the approaches I used in my project was bridging western medicine and also traditional indigenous practices." ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 3.58% to $718.16 Tuesday, on what proved to be an all-around grim trading ...